Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States.

Sundar Jagannath,Nedra Joseph,Jinghua He,Concetta Crivera,Alex Z Fu,Ashraf Garrett,Nina Shah

Oncology and therapy（2022）

引用 1|浏览3

暂无评分

摘要

In this retrospective US claims-database study, patients with MM with ≥ 4 prior LOTs, including TCE, continued to experience high healthcare costs that were mostly attributable to anti-myeloma drugs and their administration.

查看译文

关键词

Healthcare costs,Healthcare resource utilization,Multiple myeloma,Triple class exposure

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要